Barclays reissued their buy rating on shares of K2M Group (NASDAQ:KTWO) in a research report sent to investors on Tuesday morning. Barclays currently has a $25.00 price objective on the medical device company’s stock.
A number of other equities analysts have also weighed in on the stock. Needham & Company LLC restated a strong-buy rating and set a $27.00 price target (down from $29.00) on shares of K2M Group in a research report on Monday, October 9th. They noted that the move was a valuation call. BidaskClub lowered shares of K2M Group from a buy rating to a hold rating in a research report on Wednesday, December 6th. Wells Fargo & Co lowered shares of K2M Group from an outperform rating to a market perform rating and set a $23.00 price target on the stock. in a research report on Monday, December 4th. Zacks Investment Research upgraded shares of K2M Group from a sell rating to a hold rating in a research report on Wednesday, December 13th. Finally, Oppenheimer restated a buy rating and set a $24.00 price target on shares of K2M Group in a research report on Friday, November 10th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the stock. K2M Group has an average rating of Buy and a consensus price target of $24.50.
Shares of K2M Group (NASDAQ:KTWO) traded up $0.33 during midday trading on Tuesday, hitting $20.57. 279,100 shares of the stock traded hands, compared to its average volume of 423,575. K2M Group has a 1-year low of $16.44 and a 1-year high of $25.99. The firm has a market capitalization of $877.40, a price-to-earnings ratio of -21.43 and a beta of 1.34. The company has a current ratio of 3.06, a quick ratio of 1.67 and a debt-to-equity ratio of 0.29.
K2M Group (NASDAQ:KTWO) last announced its earnings results on Wednesday, November 1st. The medical device company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.01). The company had revenue of $62.65 million during the quarter, compared to analyst estimates of $62.69 million. K2M Group had a negative net margin of 16.22% and a negative return on equity of 16.02%. The firm’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same quarter last year, the business earned ($0.19) EPS. equities analysts expect that K2M Group will post -0.85 EPS for the current fiscal year.
A number of large investors have recently bought and sold shares of the business. Schwab Charles Investment Management Inc. raised its stake in shares of K2M Group by 32.1% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 174,070 shares of the medical device company’s stock valued at $4,241,000 after acquiring an additional 42,290 shares during the period. First Trust Advisors LP purchased a new stake in shares of K2M Group in the 2nd quarter valued at approximately $1,270,000. Rhumbline Advisers raised its stake in shares of K2M Group by 49.2% in the 2nd quarter. Rhumbline Advisers now owns 43,165 shares of the medical device company’s stock valued at $1,051,000 after acquiring an additional 14,241 shares during the period. Legal & General Group Plc raised its stake in shares of K2M Group by 41.4% in the 2nd quarter. Legal & General Group Plc now owns 9,561 shares of the medical device company’s stock valued at $232,000 after acquiring an additional 2,798 shares during the period. Finally, BNP Paribas Arbitrage SA raised its stake in shares of K2M Group by 5,175.3% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,484 shares of the medical device company’s stock valued at $109,000 after acquiring an additional 4,399 shares during the period. Institutional investors own 97.95% of the company’s stock.
TRADEMARK VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/12/barclays-reaffirms-buy-rating-for-k2m-group-ktwo.html.
About K2M Group
K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.
Receive News & Ratings for K2M Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group and related companies with MarketBeat.com's FREE daily email newsletter.